Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[L-DOPA-producing primary fibroblasts genetically modified with a retrovirus vector system]

A Ishida1, J Mukawa

  • 1Department of Neurosurgery, University of the Ryukyus School of Medicine, Okinawa, Japan.

No to Shinkei = Brain and Nerve
|September 1, 1995
PubMed
Summary

Genetically modified skin fibroblasts can produce L-DOPA, a key molecule for treating Parkinson's disease. These engineered cells show stable catecholamine production, offering a promising new graft strategy for gene therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cooling positronium to ultralow velocities with a chirped laser pulse train.

Nature·2024
Same author

Thermal and impact histories of 25143 Itokawa recorded in Hayabusa particles.

Scientific reports·2018
Same author

Erratum: Observation of the hyperfine spectrum of antihydrogen.

Nature·2017
Same author

Antihydrogen accumulation for fundamental symmetry tests.

Nature communications·2017
Same author

Observation of the hyperfine spectrum of antihydrogen.

Nature·2017
Same author

Observation of the 1S-2S transition in trapped antihydrogen.

Nature·2016

Area of Science:

  • Neuroscience
  • Gene Therapy
  • Cell Biology

Context:

  • Parkinson's disease treatment faces challenges with current intracerebral grafting strategies.
  • Primary skin fibroblasts offer a readily accessible cell source for transplantation.
  • Genetic modification of fibroblasts aims to restore catecholamine production.

Purpose:

  • To genetically engineer primary rat skin fibroblasts to produce L-DOPA, a precursor to dopamine.
  • To evaluate the catecholamine production and release capabilities of modified fibroblasts in vitro.
  • To assess the stability and viability of engineered fibroblasts for potential therapeutic applications.

Summary:

  • Rat skin fibroblasts were successfully transfected with human tyrosine hydroxylase (TH) cDNA using a retrovirus vector.

Related Experiment Videos

  • Supplementation with biopterin (BH4) and a foreign promoter enhanced L-DOPA production and release.
  • Engineered fibroblasts demonstrated stable L-DOPA production irrespective of cell passage number or cryopreservation duration.

    • Impact:

    • Genetically modified fibroblasts represent a promising cell graft for Parkinson's disease gene therapy.
    • This approach offers a potentially more stable and accessible alternative to current treatment strategies.
    • Successful gene integration and sustained therapeutic molecule production highlight the potential of fibroblast-based therapies.